Related Experiment Video
Updated: Feb 15, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Integrative transcriptome analysis identifies genes and pathways associated with enzalutamide resistance of prostate
Subo Qian1, Jia Xia1, Hailong Liu1
1a Department of Urology , Xinhua Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , P.R. China.
Background:
Enzalutamide, a novel androgen receptor (AR) signaling inhibitor, has been widely used to increase survival in patients with castration-resistant prostate cancer. However, resistance to enzalutamide invariably develops.
Methods:
To understand the underlying mechanisms of resistance to enzalutamide, we performed integrative analysis on multiple transcriptome datasets to identify those genes constantly up- or down-regulated in response to enzalutamide treatment.
Results:
There were 703 and 581 differentially expressed genes derived from enzalutamide-sensitive and -resistant cell lines, respectively. Functional enrichment analysis on these genes demonstrated that biological processes of cell proliferation and ubiquitin mediated proteolysis pathway are specifically disturbed in sensitive cell lines but not resistant ones. Such divergence explained why enzalutamide ineffective for resistant prostate cancer.
Conclusions:
Taken together, the present study revealed a set of critical genes, which can provide etiologic clues as to enzalutamide-resistant prostate cancer and guide novel therapeutic approaches.
Insights
Enzalutamide resistance in prostate cancer arises from altered gene expression. Identifying these gene changes offers new therapeutic targets for castration-resistant prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Enzalutamide is a key treatment for castration-resistant prostate cancer (CRPC).
- Development of resistance to enzalutamide is a significant clinical challenge in CRPC management.
Purpose of the Study:
- To elucidate the molecular mechanisms driving enzalutamide resistance in prostate cancer.
- To identify differentially expressed genes associated with enzalutamide sensitivity and resistance.
Main Methods:
- Integrative analysis of multiple transcriptome datasets.
- Identification of consistently up- or down-regulated genes following enzalutamide treatment.
- Functional enrichment analysis of identified gene sets.
Main Results:
- Identified 703 differentially expressed genes in enzalutamide-sensitive cells and 581 in resistant cells.
- Observed distinct alterations in cell proliferation and ubiquitin-mediated proteolysis pathways between sensitive and resistant cell lines.
- These pathway differences explain enzalutamide's reduced efficacy in resistant prostate cancer.
Conclusions:
- The study identified critical genes involved in enzalutamide resistance.
- These findings provide etiological insights into enzalutamide-resistant prostate cancer.
- The identified genes may guide the development of novel therapeutic strategies.
Related Concept Videos
Treatment Resistant Cancers
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Survival Analysis
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Resistivity

